Stock Track | Catalyst Pharmaceuticals Soars 8.36% as Q4 Results Beat Estimates, Fueled by FIRDAPSE and AGAMREE Growth

Stock Track

2025/02/27

Catalyst Pharmaceuticals (NASDAQ: CPRX) stock surged 8.36% in after-hours trading on Wednesday, following the company's stellar fourth-quarter 2024 and full-year financial performance, driven by strong growth in its key products, FIRDAPSE® and AGAMREE®.

The biopharmaceutical company reported record total revenues of $141.8 million for the fourth quarter, representing a 28.3% year-over-year increase and exceeding analysts' expectations. For the full year 2024, total revenues soared 23.5% to $491.7 million, marking another year of record growth.

Catalyst's flagship product, FIRDAPSE®, saw its net revenue climb 18.4% to $306 million for the full year, fueled by sustained organic growth. Additionally, the company's recently launched therapy, AGAMREE®, garnered $46 million in net revenue in 2024, reflecting its successful market adoption and strong commercial performance.

Buoyed by these impressive results and the continued momentum of its key products, Catalyst Pharmaceuticals provided an upbeat outlook for fiscal 2025. The company forecasted total revenues to be between $545 million and $565 million, highlighting its confidence in continued growth prospects.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1111439570"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1111439570\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1111439570?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-27 09:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1111439570","market":"hk","top_or_hot":-1,"title":"Stock Track | Catalyst Pharmaceuticals Soars 8.36% as Q4 Results Beat Estimates, Fueled by FIRDAPSE and AGAMREE Growth","media":"Stock Track","content":"<p>Catalyst Pharmaceuticals (NASDAQ: CPRX) stock surged 8.36% in after-hours trading on Wednesday, following the company's stellar fourth-quarter 2024 and full-year financial performance, driven by strong growth in its key products, FIRDAPSE® and AGAMREE®.</p>\n\n<p>The biopharmaceutical company reported record total revenues of $141.8 million for the fourth quarter, representing a 28.3% year-over-year increase and exceeding analysts' expectations. For the full year 2024, total revenues soared 23.5% to $491.7 million, marking another year of record growth.</p>\n\n<p>Catalyst's flagship product, FIRDAPSE®, saw its net revenue climb 18.4% to $306 million for the full year, fueled by sustained organic growth. Additionally, the company's recently launched therapy, AGAMREE®, garnered $46 million in net revenue in 2024, reflecting its successful market adoption and strong commercial performance.</p>\n\n<p>Buoyed by these impressive results and the continued momentum of its key products, Catalyst Pharmaceuticals provided an upbeat outlook for fiscal 2025. The company forecasted total revenues to be between $545 million and $565 million, highlighting its confidence in continued growth prospects.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Catalyst Pharmaceuticals Soars 8.36% as Q4 Results Beat Estimates, Fueled by FIRDAPSE and AGAMREE Growth</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Catalyst Pharmaceuticals Soars 8.36% as Q4 Results Beat Estimates, Fueled by FIRDAPSE and AGAMREE Growth\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2025-02-27 09:19</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Catalyst Pharmaceuticals (NASDAQ: CPRX) stock surged 8.36% in after-hours trading on Wednesday, following the company's stellar fourth-quarter 2024 and full-year financial performance, driven by strong growth in its key products, FIRDAPSE® and AGAMREE®.</p>\n\n<p>The biopharmaceutical company reported record total revenues of $141.8 million for the fourth quarter, representing a 28.3% year-over-year increase and exceeding analysts' expectations. For the full year 2024, total revenues soared 23.5% to $491.7 million, marking another year of record growth.</p>\n\n<p>Catalyst's flagship product, FIRDAPSE®, saw its net revenue climb 18.4% to $306 million for the full year, fueled by sustained organic growth. Additionally, the company's recently launched therapy, AGAMREE®, garnered $46 million in net revenue in 2024, reflecting its successful market adoption and strong commercial performance.</p>\n\n<p>Buoyed by these impressive results and the continued momentum of its key products, Catalyst Pharmaceuticals provided an upbeat outlook for fiscal 2025. The company forecasted total revenues to be between $545 million and $565 million, highlighting its confidence in continued growth prospects.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CPRX","symbol_name":"Catalyst Pharmaceutical Partners","start_time":0,"source_url":"","article_id":"1111439570","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1111439570","pubTimestamp":1740619154,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Catalyst Pharmaceuticals  stock surged 8.36% in after-hours trading on Wednesday, following the company's stellar fourth-quarter 2024 and full-year financial performance, driven by strong growth in its key products, FIRDAPSE and AGAMREE.The biopharmaceutical company reported record total revenues of $141.8 million for the fourth quarter, representing a 28.3% year-over-year increase and exceeding analysts' expectations. For the full year 2024, total revenues soared 23.5% to $491.7 million, markin","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CPRX":"Catalyst Pharmaceutical Partners"},"translate_title":"在FIRDAPSE和AGAMREE增长的推动下，第四季度业绩超出预期，股票赛道Catalyst Pharmaceuticals飙升8.36%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CPRX":1},"content_text":"Catalyst Pharmaceuticals (NASDAQ: CPRX) stock surged 8.36% in after-hours trading on Wednesday, following the company's stellar fourth-quarter 2024 and full-year financial performance, driven by strong growth in its key products, FIRDAPSE® and AGAMREE®.\nThe biopharmaceutical company reported record total revenues of $141.8 million for the fourth quarter, representing a 28.3% year-over-year increase and exceeding analysts' expectations. For the full year 2024, total revenues soared 23.5% to $491.7 million, marking another year of record growth.\nCatalyst's flagship product, FIRDAPSE®, saw its net revenue climb 18.4% to $306 million for the full year, fueled by sustained organic growth. Additionally, the company's recently launched therapy, AGAMREE®, garnered $46 million in net revenue in 2024, reflecting its successful market adoption and strong commercial performance.\nBuoyed by these impressive results and the continued momentum of its key products, Catalyst Pharmaceuticals provided an upbeat outlook for fiscal 2025. The company forecasted total revenues to be between $545 million and $565 million, highlighting its confidence in continued growth prospects.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}